Vascepa
Coverage of Vascepa in the Nexus archive.
- Justices reject holding generic pharmaceutical manufacturers liable for decisions of pharmacists about prescribing their products
The Supreme Court unanimously ruled that generic drug manufacturer Hikma Pharmaceuticals cannot be held liable for patent infringements by branded drugmaker Amarin Pharma, rejecting claims that Hikma's labeling, press releases, and website statements actively induced infringement. The case centered on whether Hikma's generic version of Vascepa, used interchangeably with Amarin's patented drug for cardiovascular and hypertriglyceridemia treatments, could be blamed for doctors and pharmacists using the generic for patented purposes.
- Supreme Court Backs Maker of Generic Heart Drug in 'Skinny Label' Case
The Supreme Court ruled that Amarin Pharma has not sufficiently proven that Hikma Pharmaceuticals' generic version of icosapent ethyl (Vascepa) infringes on its patents. The decision centers on a 'Skinny Label' case involving the heart drug.
- How a Supreme Court fight over fish oil could raise your prescription drug costs
The Supreme Court is set to hear Hikma v. Amarin, a patent dispute over fish oil-based drugs that could increase prescription drug costs for patients and disrupt generic drug company operations. The case centers on whether Amarin's patent for Vascepa (a fish oil drug) was invalidated by prior art, which could affect how generic manufacturers navigate patent challenges.